FDA Oncology Announcements

JAK inhibitor × Other × Clear all

2 Announcements

FDA approves ruxolitinib for chronic graft-versus-host disease

Drug: Jakafi (ruxolitinib) · JAK inhibitor
Condition: Other

FDA approves ruxolitinib for acute graft-versus-host disease

Drug: JAKAFI (ruxolitinib) · JAK inhibitor
Condition: Other